Baszucki Group Announces Six Recipients of the Metabolic Psychiatry Scholar Award for Emerging Scientific Leaders Advancing Mental Health Innovation
Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award, a new initiative that supports exceptional early-career scientists and clinicians working to advance understanding of the connection between metabolic health and mental health. The award represents a significant step forward in growing the rapidly advancing field of metabolic psychiatry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020666940/en/
Baszucki Group 2025 Metabolic Psychiatry Scholar Award Recipients
The six scholars will each receive up to $150,000 over 18 months for original research in metabolic psychiatry. The award program advances Baszucki Group’s mission to transform mental health outcomes through research at the intersection of metabolism, psychiatry, and neuroscience. Scholars will also receive mentorship, professional development, and communication support to amplify the impact of their research. The awards expand Baszucki Group’s research priorities into new diagnoses, genetics, novel combinations of treatment modalities, and implementation science.
“This award provides vital support for exceptional early-career scientists, allowing them to jumpstart innovative projects that don’t fit more traditional funding sources,” said Jan Ellison Baszucki, co-founder and president of Baszucki Group. “These outstanding awardees now have an opportunity to bring metabolic psychiatry approaches into the mainstream, paving the way for access to new treatments for the patients who need them most.”
The scholars’ work falls broadly into two subcategories: research and clinical capacity-building. Four of the awardees are engaged in translational and clinical research into the links between metabolic health and mental health:
Jacek Kolacz, PhD, Research Assistant Professor at The Ohio State University is an expert in brain-body responses to chronic stress and trauma recovery. His project, titled, “Enhancing PTSD Recovery with Metabolic-Augmented Psychotherapy” will investigate the combined effectiveness of cognitive processing therapy and metabolic therapy.
Eline Dekeyster, PhD, Assistant Professor at Leiden University, leads the Lifestyle Brain Interaction research group. Her project, “KETASE: Ketogenic Therapy for ASD: Sustainability and Efficacy,” will examine the clinical efficacy and long-term sustainability of ketogenic therapy for adults with autism, while also exploring biomarkers for outcome prediction.
Sean Nestor, MD, PhD, Assistant Professor at the University of Toronto, is a pioneer in combining neuroimaging and neuromodulation to understand the mechanisms of neurological and psychiatric disorders. His proposed work, “Ketogenic enhancement of therapeutic brain stimulation in treatment-resistant depression: A Randomized Controlled Pilot Trial,” will combine ketogenic therapy and transcranial magnetic stimulation in a first-of-its-kind trial.
Gabriel Fries, MSc, PhD, Assistant Professor at the University of Texas Health Science Center at Houston is an expert in the genetic and epigenetic underpinnings of severe mental illnesses. His project, “Deciphering the complex link between diet, metabolic dysfunction, and suicide risk,” will aim to identify the link between dietary and metabolic parameters and suicide risk.
Two of the awards will support clinical capacity-building projects, expanding support for ketogenic therapy across the UK and Canada:
Fabiano Alves Gomes, MD, MSc, PhD, Assistant Professor at McMaster University, is an expert in bipolar disorder and treatment-resistant depression and works extensively on implementing evidence-based interventions, including metabolic health and lifestyle factors. His project, “Integrating Nutritional Ketosis, Lifestyle Therapies, and Translational Research into Clinical Practice,” will establish a comprehensive Metabolic Psychiatry Program in Canada.
Erin L Bellamy, MSc, PhD, Chartered Psychologist, Ketogenic Specialist and Research Fellow at the University of East London provides Ketogenic Metabolic Therapy support to clients with a wide range of physical and mental health issues through private practice. Her project, titled, “Implementing Ketogenic Metabolic Therapy for Mental Illness: A Mixed-Methods Pilot Trial of an Online Psychoeducational and Support Program,” will expand on her pre-existing treatment program and support a rigorous evaluation protocol.
“The strength of the candidates who applied to this open call highlights the global enthusiasm to explore metabolic psychiatry's potential,” said Julie Milder, PhD, Director of Neuroscience at Baszucki Group. “From foundational research to clinical capacity building, their work has the potential to revolutionize patient treatment. We anticipate that this award marks the start of a lasting initiative that will continue to support the field for years to come.”
About Baszucki Group
Launched in 2021 by Roblox founder and Chief Executive Officer David Baszucki and best-selling author Jan Ellison Baszucki, Baszucki Group leverages private giving, impact investing, advocacy, storytelling and community building to drive foundational change. A primary objective of Baszucki Group is to transform mental health outcomes by supporting initiatives at the intersection of metabolism, psychiatry, and neuroscience. To learn more about metabolic approaches to mental disorders, including ketogenic therapy, visit Metabolic Mind, a nonprofit initiative of Baszucki Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251020666940/en/
Contacts
Baszucki Group media contact: media@baszuckigroup.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF and BASF Announce Strategic Collaboration to Drive Next-Generation Enzyme and Polymer Innovation21.10.2025 13:00:00 EEST | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced a strategic collaboration with BASF, one of the world’s largest chemical companies and leader in sustainable product innovation, to accelerate the development of IFF’s Designed Enzymatic Biomaterials™ technology platform and create next-generation enzyme technologies for fabric, dish and personal care as well as industrial cleaning applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021911702/en/ Photo credit: IFF This collaboration brings together two industry leaders with a shared vision: to develop high-performance, sustainable solutions that meet evolving consumer and market demands. By combining advanced chemical capabilities and expertise in biotechnology and protein engineering from IFF and BASF, the partnership aims to deliver breakthrough solutions at scale that enhance cleaning performance, imp
Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule21.10.2025 12:12:00 EEST | Press release
Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and pharmacokinetics of FNP-223, an orally available, potent and selective inhibitor of the OGA enzyme, in-licensed from Asceneuron, aimed at slowing disease progression in Progressive Supranuclear Palsy (PSP)1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021806533/en/ Ferrer's pharmaceutical production plant in Sant Cugat del Valles, Barcelona, Spain. PSP is a rare, rapidly progressive and ultimately fatal neurodegenerative disease2. To date, no disease-modifying therapies have been approved for PSP. The PROSPER study is a randomized, double-blind, placebo-controlled trial3 that has successfully recruited the planned number of 220 participants with PSP in just 14 months, achieving this milestone on October 6th, two months ahead
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar21.10.2025 11:51:00 EEST | Press release
Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration provides precise dosing and ease of use, supporting efficient administration for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Bioeq AG, a joint venture between Polpharma Biologics Group BV and Formycon AG, is responsible for the development and licensing of Ranivisio® PFS. Teva holds the commercialization rights for France under an exclusive licensing agreement with Bioeq. The drug substance for Ranivisio® PFS is manufactured by Polpharma Biologics S.A. - a contract development and manufacturing organization (CDMO) operating under the Rezon
NTT DATA Strengthens Global Insurance Leadership with Acquisition of Alchemy Technology Services21.10.2025 11:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the acquisition of Alchemy Technology Services, a specialist insurance technology consultancy. The move reinforces NTT DATA’s commitment to transforming the global insurance ecosystem, addressing current and emerging challenges around agility, modernization and scalability. In addition to its strong consultancy and Guidewire credentials, Alchemy brings deep expertise in the specialty insurance market, particularly in supporting complex and regulated environments, such as the London Market, the largest (re)insurance subscription market globally. This will further strengthen NTT DATA’s ability to serve niche and high-value segments across the global insurance landscape. A shared vision for insurance innovation This acquisition marks a significant milestone in NTT DATA’s strategy to lead the digital reinvention of the insurance sector - a market set to reach $230.7 billion in IT spend this year. Bui
Impartner Expands European Infrastructure to Accelerate Growth and Customer Support Across EMEA21.10.2025 11:00:00 EEST | Press release
Impartner, the leading provider of Partner Relationship Management (PRM) solutions, today announced the expansion of its European infrastructure with a new Azure-based data centre in the Netherlands. This milestone reflects Impartner’s accelerating success across the EMEA region and its commitment to providing customers with the highest levels of security, compliance, performance and support. “Our EMEA business continues to grow rapidly as companies across the region look to Impartner to scale their partner ecosystems,” said Curtis Brinkerhoff, CRO of Impartner. “Expanding our infrastructure within Europe, in close collaboration with Microsoft, ensures we are not only meeting strict EU data residency and privacy standards, but also strengthening performance and responsiveness for our customers across all industries.” By hosting in Microsoft’s Netherlands Azure data centre, Impartner customers benefit from the assurance of GDPR-compliant data handling, best-in-class security and the spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom